The approval is based on data from a Phase III trial evaluating patients who had received two or more previous treatments.

The antibody-drug conjugate, withdrawn from the market by GSK in 2022 after failing a confirmatory study, was approved ...

The Food and Drug Administration on Thursday delivered a split decision on a blood cancer drug from GSK, approving its use in ...

US regulators approved GSK Plc’s blood cancer drug, a decision that will allow the company to bring the medicine back to the ...

Three years after its global market withdrawal and months after a negative advisory committee vote, GSK can officially call it a comeback for its multiple myeloma drug Blenrep in the U.S., albeit w | ...

Against the odds, GSK has secured FDA approval for its multiple myeloma therapy Blenrep, three years after it was removed ...

GSK stock crumbled Friday after the FDA granted its blood cancer treatment, Blenrep, a narrower-than-expected approval.

CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

The new approval completes a surprise turnaround for Blenrep, which was initially cleared in 2020 but pulled from the market ...

The FDA approved belantamab mafodotin-blmf in combination with bortezomib and dexamethasone for the treatment of certain ...